FOSUN PHARMA (600196.SH): Initially repurchased 0.8128 million A-shares.

On March 26, Gelonghui reported that FOSUN PHARMA (600196.SH) announced that according to the A-share repurchase plan, the company carried out its first A-share repurchase through centralized bidding on March 26, 2025, repurchasing a total of 812,800 A-shares (approximately 0.0304% of the company's total shares outstanding as of the market close that day, which is 2,671,326,465 shares). The total repurchase amount was RMB 19.9909 million (excluding transaction costs), with an average repurchase price of RMB 24.60 per share, a maximum price of RMB 24.66 per share, and a minimum price of RMB 24.54 per share.

Gelonghui Finance05:25 ET

Fosun Pharmaceutical-Owned Gland Pharma to Invest 1.6 Billion Yuan in Indian Mutual Funds, Bonds

MT Newswires01:25 ET

Fosun Pharmaceutical Gets Nod for Kidney Disease Drug Trial

MT Newswires01:10 ET

China's NAFMII Accepts Fosun Pharma's Application to Issue Up to 10 Billion Yuan Bonds

MT Newswires00:56 ET

Press Release: Fosun Pharma Announces 2024 Annual Results

Dow Jones22:29 ET

Fosun Pharma Posts Higher 2024 Profit

MT Newswires22:05 ET

FOSUN PHARMA announced its 2024 performance, with a net income of approximately 2.77 billion yuan, an increase of 16.08% year-on-year.

FOSUN PHARMA (02196) announced its 2024 performance, achieving revenue of 41.067 billion yuan and net income attributable to shareholders of the listed company of 2.77 billion yuan, an increase of 16.08% year-on-year; basic EPS is 1.04 yuan.

Sina Hong Kong Stock.21:06 ET

Shanghai Fosun Pharma Registers RMB10 Billion in Notes and Papers

TipRanks18:23 ET

Shanghai Fosun Pharma Declares Final Dividend for 2024

TipRanks17:42 ET

Shanghai Fosun Pharmaceutical: Lower Contributions From Medical Devices, Medical Diagnosis Unit Weighed on Rev >2196.HK

Dow Jones17:21 ET

Shanghai Fosun Pharmaceutical 2024 Net CNY2.77B Vs. Net CNY2.40B >2196.HK

Dow Jones17:20 ET

Fosun Pharmaceuticals: Fosun Pharmaceuticals 2024 Annual Report

SZSI12:00 ET · Announcements

Fosun Pharmaceuticals: Fosun Pharmaceuticals 2024 Annual Report Summary

SZSI12:00 ET · Announcements

Fosun Pharmaceutical 2024 Annual Report

SZSI12:00 ET · Announcements

Fosun Pharmaceutical 2024 Annual Report Summary

SZSI12:00 ET · Announcements

Express News | Shanghai Fosun Pharmaceutical Group FY Operating Cash Flow RMB 4,477 Million

ReutersMar 25 10:53 ET

Express News | Shanghai Fosun Pharmaceutical Group FY Revenue RMB 40,910 Million

ReutersMar 25 10:53 ET

FOSUN PHARMA: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024

HKEXMar 25 10:53 ET · Announcements

FOSUN PHARMA (02196) released its 2024 annual report: Accelerating the internationalization of innovative products, with cash flow from operations increasing by 31.13% year-on-year.

On March 25, FOSUN PHARMA released the 2024 annual performance report.

Zhitong FinanceMar 25 10:04 ET

FOSUN PHARMA (600196.SH): A holding subsidiary plans to engage in finance leasing business.

Gelonghui, March 25丨FOSUN PHARMA (600196.SH) announced that in order to further broaden financing channels, some of the company's holding subsidiaries plan to use part of their own asset equipment as the transfer symbol and leasing objects, to engage in sale-and-leaseback financing leasing business with qualified financing leasing companies/financial leasing companies, with a total financing amount not exceeding 1.2 billion yuan.

Gelonghui FinanceMar 25 09:40 ET